Ramazan Eren Ramazan Eren

Dr. Ramazan Eren Ramazan Eren


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023
Verified
Journal Article
Open access
BDBaris Demirkol
Baris Demirkol
SGSule Gul
Sule Gul
MÇMustafa Çörtük
Mustafa Çörtük
NFNeslihan Akanil Fener
Neslihan Akanil Fener
EYEminegul Yavuzsan
Eminegul Yavuzsan
ECErdogan Cetinkaya
Erdogan Cetinkaya
Background: Bleomycin causes increased production of reactive oxygen species, leads to pulmonary toxicity, fibroblast activation, and fibrosis. Objectives: This study aimed to evaluate the protective effect of pirfenidone on bleomycin-induced lung toxicity in rats. Methods: Twenty-eight adult rats were randomly divided into 3 groups; Bleomycin (B group, n=10), Bleomycin and Pirfenidone (B-PND group, n=13), and the control group (n=5). The bleomycin regimen was administered for 9 weeks. Pirfenidone was administered at 100 mg/ kg daily. Total antioxidant level (TAS), total oxidant level (TOS), tumor necrosis factor (TNF-alpha), transforming growth factor (TGF-f31), matrix metalloproteinase-2 (MMP-2), plasminogen activator inhibitor (PAI) levels were studied. Histopathologically, sections were stained with Hematoxylin-eosin and Masson-trichrome for grading-scoring according to the Ashcroft score. Results: Stage 3 fibrosis was observed in 50% of the B group rats, stage 3 and higher fibrosis was never detected in the B-PND group and the difference was statistically significant (p=0.003). When evaluating tissue inflammation, the inflammation was higher in the B-PND group than in the other groups (p<0.001). Pleuritis was detected in all rats in group B, while was not observed in B-PND and control group (p<0.001). The TAS level was found to be significantly higher in group B than in group B-PND (p=0.034), while no difference was found between TOS, TNF-alpha, MMP-2, PAI, TGF-f31. Conclusions: Pirfenidone had a statistically significant protective effect in bleomycin-induced lung fibrosis and pleuritis in rats. Despite the presence of inflammation in the tissue, no significant changes were observed in inflammation markers in the peripheral blood. Novel serum biomarkers are needed to indicate the presence of inflammation and fibrosis in the lung.

8 November 2024 in Medicine
Verified
Journal Article
Open access
BDBaris Demirkol
Baris Demirkol
CSCelal Satıcı
Celal Satıcı
RERamazan Eren Ramazan Eren
Ramazan Eren Ramazan Eren
ECEfsun Gonca Ugur Chousein
Efsun Gonca Ugur Chousein
NSNaci Senkal
Naci Senkal
EÇErdoğan Çetinkaya
Erdoğan Çetinkaya
Pulmonary amyloidosis is an extremely rare disease, often detected incidentally because of its asymptomatic nature and potential to result in fatal outcomes. In this study, we aimed to present the clinical and radiological features of patients diagnosed with pulmonary amyloidosis by biopsy. This descriptive study included 21 patients with pathologically diagnosed pulmonary amyloidosis. Pulmonary amyloidosis was classified as diffuse alveolar-septal amyloidosis (DASA), cystic amyloidosis (CPA), tracheobronchial amyloidosis (TBA), nodular amyloidosis (NPA), and extraparenchymal pulmonary amyloidosis (pleural and mediastinal lymph node). Clinical, bronchoscopic, and radiological specific characteristics were presented in detail to be used for differential diagnosis. The median age of the patients was 63 (40–83) years, and 14 (66.7%) were male. Twenty patients (95.2%) presented with at least 1 comorbidity. All patients diagnosed with tracheobronchial amyloidosis were symptomatic at presentation, whereas those diagnosed with NPA/extraparenchymal amyloidosis were often asymptomatic. The patients included 1 case of DASA, 1 case of CPA, 10 cases of NPA, 6 cases of TBA, and 3 cases of extraparenchymal amyloidosis involving the mediastinal lymph node and pleura. Sixteen patients (76.2%) were classified as localized amyloidosis, while 5 patients (23.8%) were classified as systemic amyloidosis following the diagnosis of multiple myeloma, monoclonal gammopathy of undetermined significance, systemic lupus erythematosus, Sjogren’s syndrome, and B-cell lymphoma. Bronchoscopic biopsies were sufficient for diagnosis, and notably, even transbronchial needle aspiration could be a useful diagnostic method. During the follow-up, we observed that the disease remained stable without progression. However, it is important to note that patients with concurrent malignancies experience fatal outcomes. In conclusion, it is crucial to distinguish pulmonary amyloidosis from other pulmonary diseases such as malignancies, infectious diseases, and interstitial lung diseases, which may have similar clinical and radiological findings. Bronchoscopic diagnostic methods are usually sufficient for the diagnosis. Although patients with pulmonary involvement mostly remain stable during long-term follow-up without progression, it is important to consider the risk of malignancy.

24 October 2023 in La Medicina del Lavoro
Verified
Journal Article
Open access
PDF file
BDBaris Demirkol
Baris Demirkol
CSCelal Satıcı
Celal Satıcı
ETElif Tanriverdi
Elif Tanriverdi
RERamazan Eren Ramazan Eren
Ramazan Eren Ramazan Eren
EHElif Altundaş Hatman
Elif Altundaş Hatman
ECErdogan Cetinkaya
Erdogan Cetinkaya
Background: We aimed to investigate the contribution of serum IgG testing to the history of exposure in the diagnosis of fibrotic hypersensitivity pneumonitis. Methods: A single-center, retrospective, cross-sectional study including 63 patients pathologically diagnosed with fibrotic hypersensitivity pneumonitis in line with the guidelines of the American Thoracic Society. Descriptive statistics were presented and Kappa statistic was performed to evaluate the compatibility between panel and the history of exposure. Results: The median age was 63 (22-81) years and 34 (54%) were male. Forty-six patients (73%) had a positive history of exposure. Thirty-nine patients (61.9%) had a positive HP/Avian panel. The most common exposure agent was mold (34.9%), followed by parakeet (31.7%). The antibody detected the most was penicillium chrysogenum lgG (36.5%), followed by aspergillus fumigatus (31.8%). There was no compatibility between HP/Avian panel and history of exposure (kappa coefficient= 0.18, p= 0.14). When the exposure was only assessed based on the history, 4 (6.35%) patients were diagnosed as fibrotic hypersensitivity pneumonitis with low confidence, 6 (9.52%) with moderate confidence, 11 (17.46%) with high confidence and 42 (66.67%) with definite confidence; whereas 4 (6.35%) patients were diagnosed as fibrotic hypersensitivity pneumonitis with low confidence, 6 (9.52%) with moderate confidence, 9 (14.29%) patients with high confidence and 44 (69.84%) patients with definite confidence if exposure was evaluated with history and/or panel. Conclusions: Serum specific precipitating antibody panel does not seem to provide additional value to the history of exposure in the diagnosis of fibrotic hypersensitivity pneumonitis.

20 December 2023
Verified
Journal Article
Open access
SGSule Gul
Sule Gul
BDBaris Demirkol
Baris Demirkol
RERamazan Eren Ramazan Eren
Ramazan Eren Ramazan Eren
KBKursad Nuri Baydili
Kursad Nuri Baydili
BKBurcu babaoglu karan
Burcu babaoglu karan
ECErdogan Cetinkaya
Erdogan Cetinkaya
Persistent interstitial lung disease (ILD) after COVID-19 infection can lead to severe loss of respiratory function and a decrease in the quality of life. There is no consensus regarding the treatment of post-COVID-19-ILD. This study aims to investigate the effectiveness of immunosuppressive treatment for this group of patients. This retrospective observational study included patients diagnosed with post-COVID-19-ILD from 2021 to 2022. Patients who had pulmonary symptoms, required prolonged oxygen therapy, and/or had restrictive pulmonary function test (PFT) and/or DLCO <80%, with diffuse parenchymal involvement on high-resolution computed tomography (HRCT), were given immunosuppressive treatment with methylprednisolone and/or mycophenolate mofetil (MMF) and followed up for 6 months. Among the 48 patients, 35 were treated. Two patients were excluded due to discontinued treatment and passed away before the study period ended. Of 33 cases, 21 (66.6%) were treated with methylprednisolone, 11 (33%) with methylprednisolone + MMF, and 1 (0.4%) with MMF alone. Comparing baseline and 6th-month data revealed significant improvement in mMRC score, saturation (SpO2), FVC, FVC%, FEV%, and DLCO% values (p<0.005). While regression was observed in all radiologic findings, regression in ground glass and reticulation was statistically significant (p<0.005). When the 1st and 6th-month data were compared, a significant increase was observed in SpO2 and DLCO% values (p=0.016) and there was a significant regression in reticulation radiologically (p=0.01). Long-term immunosuppressive therapy may be preferred in proper cases of post-COVID-19-ILD as an effective and safe treatment option that improves the quality of life, respiratory parameters, and radiologic findings.

15 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
YİYaşar İncekara
Yaşar İncekara
EÇErdoğan Çetinkaya
Erdoğan Çetinkaya
RERamazan Eren Ramazan Eren
Ramazan Eren Ramazan Eren
RAReşit Akyel
Reşit Akyel
MÇMustafa Çörtük
Mustafa Çörtük
Background: Sarcoidosis is a multisystem inflammatory disorder characterized by non-caseating granulomas, most commonly affecting the lungs and intrathoracic lymph nodes. Angiotensin-converting enzyme (ACE) levels and calcium abnormalities are recognized biomarkers, while ^18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is increasingly used to assess disease activity. However, neither provides sufficient diagnostic accuracy alone. Therefore, this study aimed to investigate the relationship between FDG-PET/CT metabolic findings and serum ACE and calcium (Ca2+) levels as surrogate indicators of inflammatory metabolic intensity in sarcoidosis. Methods: In this retrospective single-center study, 127 patients with pulmonary sarcoidosis who underwent PET/CT at diagnosis were evaluated. Demographic and clinical data, ACE, and Ca2+ levels were recorded. FDG uptake in mediastinal, pulmonary, and extrapulmonary sites was analyzed, and correlations with biomarkers were assessed. Results: The cohort included 89 females (70.1%) and 38 males (29.9%), mean age 51.3 ± 11.9 years. FDG uptake was most frequent in mediastinal lymph nodes (84.3%) and lung parenchyma (40.9%). ACE levels correlated weakly with total SUVmax (r = 0.214, p = 0.019). Calcium levels correlated with extrapulmonary SUVmax (r = 0.327, p = 0.001) and were higher in patients with extrapulmonary involvement (p = 0.045). No associations were found between symptom presence and biomarkers or SUVmax values. Conclusions: FDG-PET/CT metabolic parameters, particularly total and extrapulmonary SUVmax, demonstrated modest yet statistically significant associations with ACE and calcium levels. These findings suggest that a combined biomarker-imaging approach may provide complementary information regarding inflammatory metabolic intensity and systemic involvement; however, the results should be interpreted as exploratory and require validation in prospective studies.

Verified
Journal Article
Open access
PDF file
MÜMelike Ülker
Melike Ülker
BDBarış Demirkol
Barış Demirkol
RERamazan Eren Ramazan Eren
Ramazan Eren Ramazan Eren
DKDilekhan Kizir
Dilekhan Kizir
CSCelal Bugra Sezen
Celal Bugra Sezen
EÇErdoğan Çetinkaya
Erdoğan Çetinkaya
Purpose: Interstitial lung disease encompasses a heterogeneous group of disorders requiring subgroup-specific treatment strategies. Surgical lung biopsy is recommended in patients who remain diagnostically unclassified despite clinical and radiological evaluation. This study aimed to evaluate the diagnostic yield, postoperative outcomes, and therapeutic impact of surgical lung biopsy in patients with interstitial lung disease. Methods: Cases of surgical biopsy performed for interstitial lung disease between 2018 and 2023 were retrospectively analyzed. All patients underwent a comprehensive preoperative evaluation, including HRCT, pulmonary function testing with DLCO analysis, bronchoscopy, and multidisciplinary assessment, before surgical biopsy was considered for diagnostically unclassified cases. Postoperative complications, mortality rates, definitive diagnoses, and treatments were evaluated. Results: A total of 253 patients were included in the study, comprising 150 males (59.3%) and 103 females (40.7%). The mean age was 58.4 ± 12.5 years. Minor complications were observed in 14 cases (5.5%), most commonly prolonged air leakage, while major complications occurred in 7 cases (2.8%), including hemorrhage requiring revision surgery and postoperative respiratory failure. Mortality was reported in two cases (0.8%). Comparison between surgical approaches demonstrated statistically significant differences regarding postoperative complication rates and drainage duration (p = 0.008, p < 0.001). All patients who received a definitive diagnosis were initiated on disease-specific treatments. Medical treatment was initiated for 197 cases (77.8%). Specific treatment was started for 174 cases (68.8%) following the determination of an interstitial subgroup diagnosis. Conclusions: Surgical lung biopsy performed via VATS is a safe procedure that provides significant diagnostic and therapeutic benefit in patients with interstitial lung disease, particularly in diagnostically unclassified cases despite multidisciplinary evaluation.